Hospital at Home (H@H)
New care pathway for vulnerable older adults.
Hospital at Home (H@H) offers hospital care at home to vulnerable older adults who would otherwise be hospitalised for acute care. The goal is to prevent hospital-related complications and (postpone) nursing home admissions. The concept is therefore a form of Right Care in the Right Place (Dutch: “Juiste Zorg op de Juiste Plaats” (JZOJP).
Commissioned by the Foundation for Effective Elderly Care (Dutch: Stichting Effectieve Ouderenzorg), Care IQ conducted an evaluation of the implementation and potential further development of H@H. They also investigated whether the lessons learned from H@H could be used to improve the suitability of other JZOJP programs for vulnerable individuals. Conversely, there are also lessons to be learned from successful JZOJP concepts. For the evaluation, dozens of stakeholders from healthcare, businesses, and Alzheimer Nederland were interviewed, supplemented with desktop research.
This research was commissioned by the Foundation for Effective Elderly Care and funded with the support of ZonMw within the framework of the Memorabel programme. Contact us for more details!
Principal Investigator: Prof. Dr. S.E.J.A. de Rooij
Intermediate Care: Hospital at Home (H@H) as a Flow Engine
Moving beyond physical beds – diverting acute pressure and designing integrated healthcare waterways.
In traditional care logistics, mounting pressure often leads to a single response: adding more hospital beds. But effective capacity management isn’t about the size of the reservoir; it’s about how we channel the flow of care.
Hospital at Home acts as a primary overflow channel and intermediate care turbine within the healthcare system. By transitioning appropriate acute care directly into the living room, we:
Read more: Not a bed, but a flow engine
AI and MedTech
Vision: AI and technology make people more important. Healthcare faces a fundamental transition. Ageing populations, growing care demand, and[…]
Patient flow and Digital Twins
Zorgsysteem onder druk? Intermediate care focust op patiëntenstroom, niet op bedden. Ontdek hoe we capaciteit en doorstroom optimaliseren.
Beyond treatment
Lessons from Novo Nordisk. What Novo Nordisk’s $1.3B Semaglutide deal teaches MedTech about the dual business case for prevention[…]
